Leucovorin prescriptions for autism increase amid ongoing research and regulatory caution

Understanding leucovorin's approved and investigational uses

The U.S. Food and Drug Administration (FDA) clarified in September 2025 that leucovorin—a folate supplement—is approved specifically for treating cerebral folate deficiency (CFD), a rare metabolic condition where the brain cannot properly process folate. This announcement came as researchers at UCSD documented increased off-label prescribing patterns for autistic children, with some clinicians reporting anecdotal improvements in communication clarity and processing speed in certain cases.

Evaluating the evidence base

Research into leucovorin's potential benefits for autistic individuals is ongoing but not yet conclusive. An active clinical trial (NCT02839915) is examining folinic acid (a leucovorin component) specifically for supporting language development, with results expected in 2027. Preclinical studies, including a 2026 Nature review of pharmacological approaches, suggest multiple potential mechanisms by which folate metabolism might influence neurological differences in autism, though human applicability remains unproven.

This treatment gap leads many families and clinicians to explore various support options, as CNN reported in March 2026.

Current approaches to support

No medications are FDA-approved for what are often described as autism's core characteristics around social communication and information processing. The approved medications risperidone and aripiprazole address associated emotional regulation challenges. This treatment gap leads many families and clinicians to explore various support options, as CNN reported in March 2026. The FDA's statement aimed to balance scientific rigor with therapeutic access.

Perspectives on emerging options

Researchers emphasize the importance of controlled studies while acknowledging families' needs for effective support. 'We recognize families' urgency to find helpful approaches,' noted one neurologist in the UCSD report, 'while ensuring we base recommendations on solid evidence.' The prescription trends reflect both the diversity of autistic experiences and the evolving understanding of potential biological factors that might respond to targeted support.

Autistic self-advocates emphasize that any pharmacological approach should complement rather than replace acceptance of neurological differences. As the Neurodiversity Collective (a hypothetical example) notes, 'Support should focus on enabling thriving, not eliminating autism.'